A randomised controlled trial of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction

iverpool Women's NHS Foundation Trust (UK)0 个研究点目标入组 112 人开始时间: 2014年7月31日最近更新: 2018年9月24日

试验速览

•1. Women with singleton pregnancy and fetus diagnosed with severe, early onset intrauterine growth restriction (IUGR) between 22+0 and 29+6 weeks of gestation and clinical decision to manage pregnancy expectantly.
•2. IUGR is defined as estimated fetal weight or abdominal circumference <10th centile and absent or reversed end diastolic velocity Doppler in the umbilical artery.
•3. 16 years of age or older
•4. Consent to take part in the trial

•1. Multiple pregnancy
•2. Known or suspected structural or chromosomal fetal abnormality
•3. Maternal illness (e.g., pre-eclampsia) that is expected to require delivery for maternal reasons within the next 72 hours
•4. Maternal wish not to have active management of the pregnancy, or to have pregnancy termination weeks
•5. Inability to give informed consent
•6. Cocaine use
•7. Contraindication to sildenafil therapy, e.g., known maternal cardiac disease, left ventricular outflow tract obstruction, concomitant treatment with nitrates or previous allergy to sildenafil

发起方

iverpool Women's NHS Foundation Trust (UK)